ReviewArteriosclerosis, thrombosis, and vascular biology2019
Diabetes Mellitus and Cardiovascular Disease.
Review in Arteriosclerosis, thrombosis, and vascular biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 4 syntheses or guidelines pooled it, 177 citations in OpenAlex.
- Relationship between elevated circulating thrombospondin-1 levels and vascular complications in diabetes mellitus.Journal of diabetes investigation · 2024Pooled it
- Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis.PloS one · 2023Pooled it
- Intermittent fasting for the prevention of cardiovascular disease.The Cochrane database of systematic reviews · 2021Pooled it
- Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.PloS one · 2021 · on this mapPooled it
- The interplay between vitamin D3 and Nrf2 signaling: mechanistic insights and therapeutic potentials.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Estimated pulse wave velocity and risk of cardiometabolic multimorbidity in middle-aged and older adults: a cohort study.BMC cardiovascular disorders · 2026Article
- Diabetic peripheral neuropathy in type 2 diabetes: prevalence and associated factors in Midwest Brazil.Archives of endocrinology and metabolism · 2026Article
- Epigenetic regulation in a high-sugar environment (Review).International journal of molecular medicine · 2026Review
- Left Atrial Strain as a Marker of Supraventricular Arrhythmia Risk in Type 2 Diabetes Mellitus.Diseases (Basel, Switzerland) · 2026Article
- Carnosol exerts anti-inflammatory effects in pulpitis by inhibiting the RAGE/NF-κB signalling pathway.Scientific reports · 2025Article
- Calcium dynamics unplugged: NCLX in disease and therapeutic frontiers.Molecular biology reports · 2025Review
- State-of-the-art wearable sensors for cardiovascular health: a review.NPJ cardiovascular health · 2025Review
- The Timeline of the Association Between Diabetes and Cardiovascular Diseases: A Narrative Review.Journal of clinical medicine · 2025Review
- Diabetes mellitus and neurocognition: A report from the Childhood Cancer Survivor Study.Cancer · 2025Article
- Associations of nontraditional lipoprotein ratios with future cardiovascular events in patients with type 2 diabetes mellitus.World journal of diabetes · 2025Article
- Vascular and Glycemic Modulation byPharmaceuticals (Basel, Switzerland) · 2025Article
- A Pilates Exercise Program as a Therapeutic Strategy in Older Adults with Type 2 Diabetes: Effects on Functional Capacity and Blood Glucose.Healthcare (Basel, Switzerland) · 2025Article
- Cell-intrinsic insulin signaling defects in human iPS cell-derived hepatocytes in type 2 diabetes.The Journal of clinical investigation · 2025Article
- Type 2 diabetes increases the risk of mortality and cardiovascular events in ischemic HFmrEF patients: a retrospective cohort study.Diabetology & metabolic syndrome · 2025Article
- Sitagliptin, diabetes mellitus, and heart failure: an in-depth review of sitagliptin therapy and heart failure in patients with diabetes mellitus.Diabetology international · 2025Review
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Cardiovascular disease remains a leading cause of morbidity and mortality in people with types 1 or 2 diabetes mellitus. Although beneficial roles for strict control of hyperglycemia have been suggested, such a strategy is not without liabilities. Specifically, the risk of hypoglycemia and its consequences remain an omnipresent threat with such approaches. The advent of the CVOT (Cardiovascular Outcomes Trials) for new antidiabetes mellitus treatments has uncovered unexpected benefits of cardiovascular protection in some of the new classes of agents, such as the GLP-1 RAs (glucagon-like peptide-1 receptor agonists) and the SGLT-2 (sodium-glucose cotransporter-2) inhibitors. Further, state-of-the-art approaches, such as antibodies to PCKSK9 (proprotein convertase subtilisin-kexin type 9); RNA therapeutics; agents targeting distinct components of the immune/inflammatory response; and novel small molecules that block the actions of RAGE (receptor for advanced glycation end products) signaling, also hold potential as new therapies for diabetes mellitus and cardiovascular disease. Finally, interventions such as weight loss, through bariatric surgery, may hold promise for benefit in diabetes and cardiovascular disease. In this Brief Review, some of the novel approaches and emerging targets for the treatment of diabetes mellitus and cardiovascular disease are discussed. Ultimately, identification of the optimal timing and combinations of such interventions, especially in the context of personalized approaches, together with emerging disease-modifying agents, holds great promise to reduce the burden that diabetes poses to the cardiovascular system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.